We expect steady progress in 4Q:F25 with revenue that was flat sequentially but up 14% year over year. We anticipate the pipeline will remain strong. We still expect the healthcare divestiture to create a headwind on revenue and margins in F2026. The company is working to expand its partnership network from delivering components to engineering solutions, which should help deepen its engagement. Most recently, it announced a partnership with Pakal Technologies (private). We think RELL remains favorably positioned to benefit from the semiconductor upcycle and the fruition of green energy solutions (GES) projects, which would be helped by lower interest rates, as this work is capital intensive. RELL generated positive operating cash flow in 3Q:F25, improved its cash balance to $36.7 million and remains debt free. The $0.24 annualized dividend, which yields 2.4%, is protected, in our opinion. Our $10 price target is based on about 17x our F2027 EPS projection of $0.55. Our moderate risk assessment is supported by the company's debt-free balance sheet, blue chip customer base, profit growth potential, strong backlog and free cash flow.